LM
SNNA

Luminus Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Luminus Management’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-949,400
Closed -$2.2M – 163
2019
Q1 		$2.2M Buy
+949,400
New +$2.57M 0.05% 108

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Luminus Management's SNNA Position: Q2 2019 in Review

Luminus Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q2 2019, closing a stake of 949,400 shares — an estimated $2.2M sold.

Luminus Management first reported a position in SNNA in Q1 2019 and held it in 1 quarter. The position peaked at $2.2M in Q1 2019. 48 funds tracked by Wall St. Rank hold SNNA as of Q2 2019.

  • Luminus Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Luminus Management sold 949,400 Sienna Biopharmaceuticals, Inc. shares in Q2 2019, an estimated $2.2M.
  • Luminus Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Luminus Management's Sienna Biopharmaceuticals, Inc. position peaked at $2.2M in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q2 2019.

Based on Luminus Management's 13F filing for Q2 2019, filed 14 Aug 2019.